Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
32
SPRY Quote, Financials, Valuation and Earnings
Last price:
$10.95
Seasonality move
:
3.32%
Day range:
$10.85 - $11.43
52-week range:
$6.66 - $18.90
Dividend yield:
0%
P/E ratio:
174.21x
P/S ratio:
7.64x
P/B ratio:
7.43x
Volume:
1.3M
Avg. volume:
1.7M
1-year change:
-2.12%
Market cap:
$1.1B
Revenue:
$89.1M
EPS (TTM):
-$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$26.9M | -$0.47 | 217.32% | -60.36% | $28.83 |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | -- |
|
INSP
Inspire Medical Systems, Inc.
|
$262.3M | $0.67 | 9.42% | -41.59% | $140.13 |
|
LPCN
Lipocine, Inc.
|
$116K | -- | -96.68% | -- | $6.88 |
|
MBX
MBX Biosciences, Inc.
|
-- | -$0.62 | -- | -32.58% | $59.25 |
|
VVOS
Vivos Therapeutics, Inc.
|
$7.2M | -$0.53 | 94.7% | -10.42% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$11.10 | $28.83 | $1.1B | 174.21x | $0.00 | 0% | 7.64x |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
INSP
Inspire Medical Systems, Inc.
|
$99.03 | $140.13 | $2.9B | 67.93x | $0.00 | 0% | 3.37x |
|
LPCN
Lipocine, Inc.
|
$7.52 | $6.88 | $41.8M | -- | $0.00 | 0% | 9.33x |
|
MBX
MBX Biosciences, Inc.
|
$32.55 | $59.25 | $1.1B | -- | $0.00 | 0% | -- |
|
VVOS
Vivos Therapeutics, Inc.
|
$2.28 | $5.50 | $20.4M | -- | $0.00 | 0% | 1.13x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
39.84% | -0.762 | 9.84% | 6.38x |
|
CV
Central Vermont Public Service Corp.
|
-- | 0.000 | -- | -- |
|
INSP
Inspire Medical Systems, Inc.
|
4.66% | -0.753 | 1.51% | 3.89x |
|
LPCN
Lipocine, Inc.
|
-- | -1.947 | -- | 7.84x |
|
MBX
MBX Biosciences, Inc.
|
0.16% | 0.977 | 0.11% | 32.47x |
|
VVOS
Vivos Therapeutics, Inc.
|
83.15% | 1.547 | 48.77% | 0.77x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SPRY
ARS Pharmaceuticals, Inc.
|
$24.3M | -$53.2M | -35.53% | -38.98% | -163.66% | -$47.2M |
|
CV
Central Vermont Public Service Corp.
|
-- | -- | -- | -- | -- | -- |
|
INSP
Inspire Medical Systems, Inc.
|
$192.7M | $9.6M | 6.32% | 6.62% | 4.3% | $58.1M |
|
LPCN
Lipocine, Inc.
|
$100.5K | -$3.4M | -30.22% | -30.22% | -2932.81% | -$3M |
|
MBX
MBX Biosciences, Inc.
|
-$100K | -$23.9M | -29.32% | -29.36% | -- | -$21.9M |
|
VVOS
Vivos Therapeutics, Inc.
|
$3.6M | -$4.7M | -153.33% | -315.1% | -69.79% | -$4.1M |
ARS Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SPRY or CV?
Central Vermont Public Service Corp. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of --. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Central Vermont Public Service Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M CVCentral Vermont Public Service Corp.-- -- -- -
What do Analysts Say About SPRY or CV?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 159.76%. On the other hand Central Vermont Public Service Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Central Vermont Public Service Corp., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Central Vermont Public Service Corp..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 CVCentral Vermont Public Service Corp.0 0 0 -
Is SPRY or CV More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.796, which suggesting that the stock is 20.356% less volatile than S&P 500. In comparison Central Vermont Public Service Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SPRY or CV?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Central Vermont Public Service Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Central Vermont Public Service Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or CV?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Central Vermont Public Service Corp. quarterly revenues of --. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is higher than Central Vermont Public Service Corp.'s net income of --. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Central Vermont Public Service Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.64x versus -- for Central Vermont Public Service Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.64x 174.21x $32.5M -$51.2M CVCentral Vermont Public Service Corp.-- -- -- --
-
Which has Higher Returns SPRY or INSP?
Inspire Medical Systems, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of 4.42%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Inspire Medical Systems, Inc.'s return on equity of 6.62%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M INSPInspire Medical Systems, Inc.85.85% $0.34 $699M -
What do Analysts Say About SPRY or INSP?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 159.76%. On the other hand Inspire Medical Systems, Inc. has an analysts' consensus of $140.13 which suggests that it could grow by 41.37%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Inspire Medical Systems, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Inspire Medical Systems, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 INSPInspire Medical Systems, Inc.9 6 0 -
Is SPRY or INSP More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.796, which suggesting that the stock is 20.356% less volatile than S&P 500. In comparison Inspire Medical Systems, Inc. has a beta of 0.725, suggesting its less volatile than the S&P 500 by 27.474%.
-
Which is a Better Dividend Stock SPRY or INSP?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Inspire Medical Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or INSP?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are smaller than Inspire Medical Systems, Inc. quarterly revenues of $224.5M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Inspire Medical Systems, Inc.'s net income of $9.9M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Inspire Medical Systems, Inc.'s PE ratio is 67.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.64x versus 3.37x for Inspire Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.64x 174.21x $32.5M -$51.2M INSPInspire Medical Systems, Inc.3.37x 67.93x $224.5M $9.9M
-
Which has Higher Returns SPRY or LPCN?
Lipocine, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -2780.8%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Lipocine, Inc.'s return on equity of -30.22%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M LPCNLipocine, Inc.87.7% -$0.59 $14.1M -
What do Analysts Say About SPRY or LPCN?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 159.76%. On the other hand Lipocine, Inc. has an analysts' consensus of $6.88 which suggests that it could fall by -8.58%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Lipocine, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Lipocine, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 LPCNLipocine, Inc.2 0 0 -
Is SPRY or LPCN More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.796, which suggesting that the stock is 20.356% less volatile than S&P 500. In comparison Lipocine, Inc. has a beta of 0.924, suggesting its less volatile than the S&P 500 by 7.65%.
-
Which is a Better Dividend Stock SPRY or LPCN?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lipocine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lipocine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or LPCN?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Lipocine, Inc. quarterly revenues of $114.6K. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Lipocine, Inc.'s net income of -$3.2M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Lipocine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.64x versus 9.33x for Lipocine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.64x 174.21x $32.5M -$51.2M LPCNLipocine, Inc.9.33x -- $114.6K -$3.2M
-
Which has Higher Returns SPRY or MBX?
MBX Biosciences, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of --. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat MBX Biosciences, Inc.'s return on equity of -29.36%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M MBXMBX Biosciences, Inc.-- -$0.63 $388.2M -
What do Analysts Say About SPRY or MBX?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 159.76%. On the other hand MBX Biosciences, Inc. has an analysts' consensus of $59.25 which suggests that it could grow by 82.03%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than MBX Biosciences, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than MBX Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 MBXMBX Biosciences, Inc.7 0 1 -
Is SPRY or MBX More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.796, which suggesting that the stock is 20.356% less volatile than S&P 500. In comparison MBX Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SPRY or MBX?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MBX Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. MBX Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or MBX?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than MBX Biosciences, Inc. quarterly revenues of --. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than MBX Biosciences, Inc.'s net income of -$21.6M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while MBX Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.64x versus -- for MBX Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.64x 174.21x $32.5M -$51.2M MBXMBX Biosciences, Inc.-- -- -- -$21.6M
-
Which has Higher Returns SPRY or VVOS?
Vivos Therapeutics, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -79.61%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Vivos Therapeutics, Inc.'s return on equity of -315.1%.
Company Gross Margin Earnings Per Share Invested Capital SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M VVOSVivos Therapeutics, Inc.52.38% -$0.49 $15M -
What do Analysts Say About SPRY or VVOS?
ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 159.76%. On the other hand Vivos Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 141.76%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Vivos Therapeutics, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Vivos Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRYARS Pharmaceuticals, Inc.6 0 0 VVOSVivos Therapeutics, Inc.2 1 0 -
Is SPRY or VVOS More Risky?
ARS Pharmaceuticals, Inc. has a beta of 0.796, which suggesting that the stock is 20.356% less volatile than S&P 500. In comparison Vivos Therapeutics, Inc. has a beta of 6.895, suggesting its more volatile than the S&P 500 by 589.464%.
-
Which is a Better Dividend Stock SPRY or VVOS?
ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vivos Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vivos Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRY or VVOS?
ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Vivos Therapeutics, Inc. quarterly revenues of $6.8M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Vivos Therapeutics, Inc.'s net income of -$5.4M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Vivos Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 7.64x versus 1.13x for Vivos Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRYARS Pharmaceuticals, Inc.7.64x 174.21x $32.5M -$51.2M VVOSVivos Therapeutics, Inc.1.13x -- $6.8M -$5.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
